Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (27) clinical trials

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

The open-label, multicenter, multinational rollover study is intended to evaluate the safety of CC-486, while providing continued treatment with CC-486 for subjects who are receiving single agent CC-486 at the time of transition to the rollover study and tolerated the protocol prescribed regimen in Celgene-sponsored trials, and whom in the ...


PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Study Treatments: Epsilon aminocaproic acid (EACA) vs. standard prophylactic platelet transfusions. Study Title: Randomized Trial of Epsilon Aminocaproic Acid versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients with Hematological Malignancies. (PROBLEMA trial: PRevention Of BLeeding in hEmatological Malignancies with Antifibrinolytic agents (epsilon aminocaproic acid). Phase: Randomized Phase ...


BGJ398 for Patients With Tumors With FGFR Genetic Alterations

The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.


A clinical trial seeking patients for a research study for the treatment of Blood disorder, Multiple Myeloma, MYELODYSPLASTIC SYNDROME, MYELOPROLIFERATIVE DISORDER, Lymphoma, Preleukemia

Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and multiple myeloma (MM) can now be cured by allogeneic bone marrow transplantation (BMT). This curative effect has been ascribed to the use ...


Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: - Determine the overall survival rate at day 200 in patients with hematologic cancers or other diseases who undergo allogeneic peripheral blood stem cell transplantation using the CliniMACS® CD34 Reagent System for T-cell depletion followed by delayed T-cell add-back. - Determine the safety of this regimen, in terms of ...


Umbilical Cord Blood Transplant Cyclophosphamide Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematologic Disease

PRIMARY OBJECTIVES: I. To determine the one year survival of patients undergoing umbilical cord blood transplantation (UCBT) after a myeloablative preparative regimen consisting of cyclophosphamide (CY), fludarabine phosphate (fludarabine [FLU]), and fractionated total body irradiation (TBI). SECONDARY OBJECTIVES: I. Incidence of transplant-related mortality (TRM) at 6 months. II. Chimerism at ...


Allogeneic Hematopoietic Stem Cell Transplantation

Primary criterion - Hematological reconstitution and chimerism post-transplantation Secondary criteria - Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions - Analysis of variations in post-transplantation immunological function profiles - Median duration of response in therapy-responsive patients and median duration ...


A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

This research protocol has been developed for patients undergoing matched-sibling hematopoietic stem cell transplant (HSCT). The patients who are treated according to this 2 step allogeneic HSCT protocol will receive cyclophosphamide to induce in-vivo tolerization of both autologous and allogeneic lymphocytes, followed by an allogeneic CD34-selected HSCT. The primary research ...


Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft

Primary Objective Estimate event free survival (EFS) (relapse, progression, or death) rate one year after transplant. Secondary Objectives: Estimate the cumulative incidences of severe acute grade III or higher GVHD, chronic GVHD (overall and by extent) Estimate the cumulative incidence of systemic steroid initiation, Summarize the graft failure frequency, Summarize ...


Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation

PATIENT ENROLMENT. It is expected that about 15 patients / year will be enrolled in this phase I-II protocol. Patient selection will be based on the following criteria: Eligibility Criteria: Any patient with one of the following lympho or myeloproliferative malignancies or syndromes in whom allogeneic NST is warranted. Patients ...